In Brief

In the space of 48 hours, the vitiligo treatment landscape shifted.

On July 29, the European Commission approved Rinvoq (upadacitinib) as the first systemic medicine for non-segmental vitiligo in the European Union. The next day, Pfizer reported positive Phase 3 results for Litfulo (ritlecitinib), another oral therapy being developed for the condition.

These are two separate events at different stages. Rinvoq is now approved in Europe. Litfulo still has to pass through regulatory review. Together, they show how quickly systemic treatment for vitiligo is moving from clinical trials into real-world medicine.

What’s Inside This Story

1. Rinvoq gets the European green light
2. Litfulo clears its Phase 3 hurdles
3. Two developments, but a larger field
4. What this actually means

For years, the only medicines approved specifically for vitiligo were topical. That was a major advance, especially for people with limited disease. But applying cream becomes less practical when vitiligo covers large areas, continues to spread or affects parts of the body that respond poorly.

Systemic treatment has been the missing piece. Europe now has its first approved option.

Rinvoq gets the European green light

The European Commission has approved AbbVie’s Rinvoq 15 mg once daily for adults and adolescents aged 12 and older with non-segmental vitiligo who are candidates for systemic therapy.

It is the first and currently only systemic medicine approved in the European Union specifically for non-segmental vitiligo.

The approval is based on the Viti-Up Phase 3 program, which included two randomized, placebo-controlled studies and 614 participants across 90 sites.

At Week 48, 19.4% and 21.5% of patients taking Rinvoq achieved T-VASI 50, compared with 5.9% on placebo in both studies.

For the face, 25.2% and 23.4% achieved F-VASI 75, compared with 5.9% and 6.9% on placebo.

Most participants did not reach those particular thresholds within the first year. Some may still have experienced smaller improvements that mattered to them, while others may require more time or a different treatment strategy.

Responses generally increased through Week 48, supporting something clinicians have observed for years: repigmentation is slow. Melanocytes, it seems, have little respect for our preferred deadlines.

Rinvoq also met ranked secondary endpoints, including a measure of disease stabilization among participants whose vitiligo was actively progressing when they entered the studies.

Its safety profile was generally consistent with experience from Rinvoq’s other approved uses, and AbbVie reported no new safety signals in the vitiligo trials. That does not mean the medicine is risk-free. Rinvoq is a systemic JAK inhibitor with established warnings and requires appropriate patient selection, screening and monitoring.

The drug remains under FDA review for vitiligo in the United States.

One final detail points to a larger story. The EMA’s scientific committee issued its positive recommendation on June 25—World Vitiligo Day. The European Commission completed the approval just over a month later. That date is becoming more than an awareness day. We will return to it in our follow-up.

Read AbbVie’s European approval announcement

Litfulo clears its Phase 3 hurdles

On July 30, Pfizer announced positive topline results from TRANQUILLO and TRANQUILLO 2, its two pivotal Phase 3 studies of Litfulo in non-segmental vitiligo.

Together, the trials enrolled 2,174 patients across 271 sites, making this the largest Phase 3 program to date for an oral systemic treatment in non-segmental vitiligo.

TRANQUILLO evaluated Litfulo 50 mg once daily in 607 adults and adolescents aged 12 and older. TRANQUILLO 2 evaluated 50 mg and 100 mg once daily in 1,567 adults.

Across the program, both doses produced significant improvements over placebo in facial and total-body repigmentation. More patients taking Litfulo achieved F-VASI 75 and T-VASI 50 at Week 52.

Pfizer has not yet released the actual response percentages, so comparisons with Rinvoq—or with other investigational oral therapies—would be premature. Topline announcements tell us whether the studies succeeded. They rarely tell us everything we would like to know over coffee.

The studies included people with active and stable disease across a broad range of severity. That matters because vitiligo does not follow one tidy clinical pattern. Some people are trying to stop rapid progression. Others have stable patches and are focused mainly on repigmentation.

Safety was consistent with Litfulo’s established profile in alopecia areata, where the drug is already approved. Pfizer reported no new safety signals, and rates of treatment-emergent adverse events were similar across the study groups.

Pfizer now plans to pursue global regulatory filings for adults with non-segmental vitiligo. That adult-only initial strategy is worth noting because TRANQUILLO included adolescents, while Rinvoq’s new European indication already covers patients aged 12 and older.

Full Litfulo results are expected at a future medical meeting.

Read Pfizer’s Phase 3 announcement

Two developments, but a larger field

Rinvoq and Litfulo work differently within the JAK signaling system. Upadacitinib preferentially inhibits JAK1-related signaling, while ritlecitinib targets JAK3 and the TEC family of kinases.

They are also not alone.

In April 2026, Incyte reported positive Phase 3 results for povorcitinib, another oral JAK1 inhibitor being studied in non-segmental vitiligo. Regulatory filings for that program are planned for the first half of 2027.

So the larger story is not that two oral JAK inhibitors have suddenly appeared. It is that three different oral programs have now produced positive Phase 3 results—and one has crossed the regulatory finish line in Europe.

That is a far stronger signal than any single trial.

Read Incyte’s Phase 3 update

What this actually means

These are not miracle pills.

Rinvoq’s results show that substantial repigmentation is possible for a meaningful minority of patients within 48 weeks. They also show that many patients will not reach the main trial thresholds during that period.

For Litfulo, we still need the full response rates, subgroup analyses and longer-term results. We also need to understand how well repigmentation is maintained, what happens after treatment stops and which patients are most likely to benefit.

Safety will matter. So will cost, insurance coverage, access to specialists and the practical burden of long-term monitoring. An approved treatment that patients cannot obtain remains scientifically impressive and clinically decorative.

Oral therapies may eventually be combined with phototherapy or other approaches, but those strategies need proper evidence before they become treatment rules.

Still, the direction is unmistakable.

Vitiligo is leaving the “cosmetic only” corner of medicine and entering the same therapeutic conversation as other immune-mediated diseases. Topical treatment is no longer the end of the road. Systemic options are arriving, competition is growing and regulators are taking the condition seriously.

That shift did not happen overnight. But during two days at the end of July, it became much harder to ignore.

And the story may have started a month earlier, on June 25—a date that is rapidly becoming more than an awareness day. It is becoming a global deadline for the vitiligo community.

We will explore that next.

— Yan Valle, Prof. h.c.
CEO, Vitiligo Research Foundation

Suggested Reading

The Vitiligo Corporate Trench Map

How patient visibility, stubborn science and corporate confidence turned vitiligo into a serious therapeutic category.

AI Shopping for Therapies: How Cognitive Surrender Is Reshaping Pharmaceutical Marketing

Why therapy discovery is becoming a recommendation problem—and what cognitive surrender means for pharmaceutical marketing.

The Vitiligo Paradox – Common Disease, Rare Funding

Four decades of data expose a common, scientifically rich disease still surviving on remarkably modest public funding.

Listen to Deep Dive in Vitiligo

🎙️ The Vitiligo Corporate Trench Map (Ep. 61)

The “Incyte effect,” pharmaceutical heavyweights, emerging biotechs and the forces reshaping the field in 2026.

🎙️ The State of Vitiligo 2025: A Fast-Moving Field With Slow-Moving Funding (Ep. 57)

Tiny public research budgets meet a booming commercial market, crowded pipelines and a stubborn infrastructure gap.

🎙️ Inside Incyte: Bridging Science and Advocacy in Vitiligo (Ep. 43)

A rare trip inside the research labs—and a candid look at what changes when scientists and patients share the same table.